These inhibitors collectively disrupt the proteolytic cascade initiated by the uPA-uPAR axis, which is crucial for tumor metastasis and matrix remodeling, making them promising agents in anti-cancer therapy [154]. The gene discussed is PLAU; the disease is neoplasm.